FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2900524832> ?p ?o ?g. }

• W2900524832 endingPage "716" @default.
• W2900524832 startingPage "707" @default.
• W2900524832 abstract "Studies have indicated an association between UDP ‐glucuronosyltransferase‐1A1 ( UGT 1A1 ) genetic polymorphisms and irinotecan‐induced toxicity. We undertook this study to investigate the association between UGT 1A1 genetic polymorphisms and toxicity in patients treated with the FOLFIRINOX (comprising oxaliplatin, irinotecan, fluorouracil, and leucovorin) chemotherapy regimen in the JASPAC 06 study. Patients screened for UGT 1A1*6 and UGT 1A1*28, and treated with either the original FOLFIRINOX (oxaliplatin 85 mg/m 2 , irinotecan 180 mg/m 2 , leucovorin 200 mg/m 2 , bolus 5‐fluorouracil [5‐ FU ] 400 mg/m 2 , and continuous 5‐ FU 2400 mg/m 2 ) or a modified FOLFIRINOX (oxaliplatin 85 mg/m 2 , irinotecan 150 mg/m 2 , leucovorin 200 mg/m 2 , and continuous 5‐ FU 2400 mg/m 2 ) as first‐line chemotherapy were included. Of 199 patients eligible for this analysis, 79 patients were treated with the original FOLFIRINOX regimen and 120 patients were treated with the modified FOLFIRINOX regimen. In the original FOLFIRINOX group, 54 were UGT 1A1 WT, and 25 were UGT 1A1 heterozygous type (−/*6, 12 patients; −/*28, 13 patients). In the modified FOLFIRINOX group, 64 were UGT 1A1 WT and 56 were UGT 1A1 heterozygous type (−/*6, 33 patients; −/*28, 23 patients). In the original FOLFIRINOX group, the incidence of diarrhea was significantly higher among patients with UGT 1A1 heterozygous type than among those with UGT 1A1 WT and the incidence of leukopenia and diarrhea was significantly higher among patients with UGT 1A1 −/*6 than among those with UGT 1A1 −/*28. Patients with UGT 1A1 heterozygous type, especially those with UGT 1A1 −/*6, tended to show a higher incidence rate of severe adverse events, but this was not statistically significant. However, for patients who received the modified FOLFIRINOX , there was no difference in the frequency of adverse events due to UGT 1A1 status. In conclusion, patients with heterozygous UGT 1A1 polymorphisms treated with the original FOLFIRINOX regimen experienced severe toxicity more frequently than patients with WT UGT 1A1 ." @default.
• W2900524832 created "2018-11-29" @default.
• W2900524832 creator A5000230079 @default.
• W2900524832 creator A5004637658 @default.
• W2900524832 creator A5011322449 @default.
• W2900524832 creator A5015481734 @default.
• W2900524832 creator A5021509769 @default.
• W2900524832 creator A5025322668 @default.
• W2900524832 creator A5027703501 @default.
• W2900524832 creator A5029696370 @default.
• W2900524832 creator A5034675205 @default.
• W2900524832 creator A5043104023 @default.
• W2900524832 creator A5045684148 @default.
• W2900524832 creator A5054771200 @default.
• W2900524832 creator A5060723984 @default.
• W2900524832 creator A5061777118 @default.
• W2900524832 creator A5065581439 @default.
• W2900524832 creator A5073758207 @default.
• W2900524832 creator A5074130054 @default.
• W2900524832 creator A5090555589 @default.
• W2900524832 date "2018-12-12" @default.
• W2900524832 modified "2023-10-17" @default.
• W2900524832 title "Impact of<i><scp>UGT</scp>1A1</i>genetic polymorphism on toxicity in unresectable pancreatic cancer patients undergoing<scp>FOLFIRINOX</scp>" @default.
• W2900524832 cites W1963555830 @default.
• W2900524832 cites W1965164852 @default.
• W2900524832 cites W1978852093 @default.
• W2900524832 cites W2011980082 @default.
• W2900524832 cites W2019030873 @default.
• W2900524832 cites W2021622287 @default.
• W2900524832 cites W2025480875 @default.
• W2900524832 cites W2032669985 @default.
• W2900524832 cites W2046530039 @default.
• W2900524832 cites W2048348819 @default.
• W2900524832 cites W2061587734 @default.
• W2900524832 cites W2062905312 @default.
• W2900524832 cites W2089755320 @default.
• W2900524832 cites W2096033615 @default.
• W2900524832 cites W2107262592 @default.
• W2900524832 cites W2118385151 @default.
• W2900524832 cites W2119347977 @default.
• W2900524832 cites W2121960517 @default.
• W2900524832 cites W2136866696 @default.
• W2900524832 cites W2151253787 @default.
• W2900524832 cites W2322536880 @default.
• W2900524832 cites W2323248054 @default.
• W2900524832 cites W2481516632 @default.
• W2900524832 cites W2802951943 @default.
• W2900524832 cites W2890063660 @default.
• W2900524832 cites W3005597110 @default.
• W2900524832 cites W4229719081 @default.
• W2900524832 doi "https://doi.org/10.1111/cas.13883" @default.
• W2900524832 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6361560" @default.
• W2900524832 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30447099" @default.
• W2900524832 hasPublicationYear "2018" @default.
• W2900524832 type Work @default.
• W2900524832 sameAs 2900524832 @default.
• W2900524832 citedByCount "20" @default.
• W2900524832 countsByYear W29005248322019 @default.
• W2900524832 countsByYear W29005248322020 @default.
• W2900524832 countsByYear W29005248322021 @default.
• W2900524832 countsByYear W29005248322022 @default.
• W2900524832 countsByYear W29005248322023 @default.
• W2900524832 crossrefType "journal-article" @default.
• W2900524832 hasAuthorship W2900524832A5000230079 @default.
• W2900524832 hasAuthorship W2900524832A5004637658 @default.
• W2900524832 hasAuthorship W2900524832A5011322449 @default.
• W2900524832 hasAuthorship W2900524832A5015481734 @default.
• W2900524832 hasAuthorship W2900524832A5021509769 @default.
• W2900524832 hasAuthorship W2900524832A5025322668 @default.
• W2900524832 hasAuthorship W2900524832A5027703501 @default.
• W2900524832 hasAuthorship W2900524832A5029696370 @default.
• W2900524832 hasAuthorship W2900524832A5034675205 @default.
• W2900524832 hasAuthorship W2900524832A5043104023 @default.
• W2900524832 hasAuthorship W2900524832A5045684148 @default.
• W2900524832 hasAuthorship W2900524832A5054771200 @default.
• W2900524832 hasAuthorship W2900524832A5060723984 @default.
• W2900524832 hasAuthorship W2900524832A5061777118 @default.
• W2900524832 hasAuthorship W2900524832A5065581439 @default.
• W2900524832 hasAuthorship W2900524832A5073758207 @default.
• W2900524832 hasAuthorship W2900524832A5074130054 @default.
• W2900524832 hasAuthorship W2900524832A5090555589 @default.
• W2900524832 hasBestOaLocation W29005248321 @default.
• W2900524832 hasConcept C121608353 @default.
• W2900524832 hasConcept C126322002 @default.
• W2900524832 hasConcept C2776694085 @default.
• W2900524832 hasConcept C2777148230 @default.
• W2900524832 hasConcept C2780259306 @default.
• W2900524832 hasConcept C2780456651 @default.
• W2900524832 hasConcept C2780962732 @default.
• W2900524832 hasConcept C2781413609 @default.
• W2900524832 hasConcept C526805850 @default.
• W2900524832 hasConcept C71924100 @default.
• W2900524832 hasConcept C90924648 @default.
• W2900524832 hasConcept C98274493 @default.
• W2900524832 hasConceptScore W2900524832C121608353 @default.
• W2900524832 hasConceptScore W2900524832C126322002 @default.
• W2900524832 hasConceptScore W2900524832C2776694085 @default.
• W2900524832 hasConceptScore W2900524832C2777148230 @default.

• next